First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

PURPOSE: Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. PATIENTS AND METHODS: We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Goetz, Matthew P., Suman, Vera J., Reid, Joel M., Northfelt, Don W., Mahr, Michael A., Ralya, Andrew T., Kuffel, Mary, Buhrow, Sarah A., Safgren, Stephanie L., McGovern, Renee M., Black, John, Dockter, Travis, Haddad, Tufia, Erlichman, Charles, Adjei, Alex A., Visscher, Dan, Chalmers, Zachary R., Frampton, Garrett, Kipp, Benjamin R., Liu, Minetta C., Hawse, John R., Doroshow, James H., Collins, Jerry M., Streicher, Howard, Ames, Matthew M., Ingle, James N.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5648176/
https://ncbi.nlm.nih.gov/pubmed/28854070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.3246
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados